Aspirin and prostate cancer prevention

Cristina Bosetti, Valentina Rosato, Silvano Gallus, Carlo La Vecchia

Research output: Contribution to journalArticle

Abstract

Aspirin has been associated to a reduced risk of colorectal, and possibly of other cancers. Data from at least 25 observational studies also suggest a modest reduced risk of prostate cancer in regular aspirin users, with a summary relative risk, RR, of 0.91 (95 % confidence interval, CI, 0.86-0.96) overall, 0.87 (95 % CI 0.74-1.02) from nine case-control studies, and 0.92 (95 % CI 0.87-0.97) from 16 cohort studies. However, risk estimates are heterogeneous and there is no relation with frequency, dose, or duration of aspirin use. Data from randomized controlled trials of aspirin for the prevention of vascular events showed a nonsignificant reduced risk of death from prostate cancer after a latent period of five or more years (RR 0.52, 95 % CI 0.20-1.24) based on 37 deaths from prostate cancer from seven trials. The RR was 0.81 (95 % CI 0.61-1.06) after 20 years of follow-up, based on 210 cases from three trials with long-term follow-up. Thus, data from observational studies and clinical trials are compatible with a modest favorable effect of aspirin on prostate cancer. Inference for causality and public health implications are, however, far from conclusive given the heterogeneity of results and the lack of dose and duration-risk relationships. Data on prostate cancer survival are still limited and inconsistent.

Original languageEnglish
Pages (from-to)93-100
Number of pages8
JournalRecent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer
Volume202
DOIs
Publication statusPublished - 2014

Fingerprint

Aspirin
Prostatic Neoplasms
Observational Studies
Causality
Blood Vessels
Case-Control Studies
Cohort Studies
Randomized Controlled Trials
Public Health
Clinical Trials
Confidence Intervals
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Aspirin and prostate cancer prevention. / Bosetti, Cristina; Rosato, Valentina; Gallus, Silvano; La Vecchia, Carlo.

In: Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, Vol. 202, 2014, p. 93-100.

Research output: Contribution to journalArticle

@article{3ccfc9f19d14454a825c747acb7db657,
title = "Aspirin and prostate cancer prevention",
abstract = "Aspirin has been associated to a reduced risk of colorectal, and possibly of other cancers. Data from at least 25 observational studies also suggest a modest reduced risk of prostate cancer in regular aspirin users, with a summary relative risk, RR, of 0.91 (95 {\%} confidence interval, CI, 0.86-0.96) overall, 0.87 (95 {\%} CI 0.74-1.02) from nine case-control studies, and 0.92 (95 {\%} CI 0.87-0.97) from 16 cohort studies. However, risk estimates are heterogeneous and there is no relation with frequency, dose, or duration of aspirin use. Data from randomized controlled trials of aspirin for the prevention of vascular events showed a nonsignificant reduced risk of death from prostate cancer after a latent period of five or more years (RR 0.52, 95 {\%} CI 0.20-1.24) based on 37 deaths from prostate cancer from seven trials. The RR was 0.81 (95 {\%} CI 0.61-1.06) after 20 years of follow-up, based on 210 cases from three trials with long-term follow-up. Thus, data from observational studies and clinical trials are compatible with a modest favorable effect of aspirin on prostate cancer. Inference for causality and public health implications are, however, far from conclusive given the heterogeneity of results and the lack of dose and duration-risk relationships. Data on prostate cancer survival are still limited and inconsistent.",
author = "Cristina Bosetti and Valentina Rosato and Silvano Gallus and {La Vecchia}, Carlo",
year = "2014",
doi = "10.1007/978-3-642-45195-9-11",
language = "English",
volume = "202",
pages = "93--100",
journal = "Recent Results in Cancer Research",
issn = "0080-0015",
publisher = "Springer New York",

}

TY - JOUR

T1 - Aspirin and prostate cancer prevention

AU - Bosetti, Cristina

AU - Rosato, Valentina

AU - Gallus, Silvano

AU - La Vecchia, Carlo

PY - 2014

Y1 - 2014

N2 - Aspirin has been associated to a reduced risk of colorectal, and possibly of other cancers. Data from at least 25 observational studies also suggest a modest reduced risk of prostate cancer in regular aspirin users, with a summary relative risk, RR, of 0.91 (95 % confidence interval, CI, 0.86-0.96) overall, 0.87 (95 % CI 0.74-1.02) from nine case-control studies, and 0.92 (95 % CI 0.87-0.97) from 16 cohort studies. However, risk estimates are heterogeneous and there is no relation with frequency, dose, or duration of aspirin use. Data from randomized controlled trials of aspirin for the prevention of vascular events showed a nonsignificant reduced risk of death from prostate cancer after a latent period of five or more years (RR 0.52, 95 % CI 0.20-1.24) based on 37 deaths from prostate cancer from seven trials. The RR was 0.81 (95 % CI 0.61-1.06) after 20 years of follow-up, based on 210 cases from three trials with long-term follow-up. Thus, data from observational studies and clinical trials are compatible with a modest favorable effect of aspirin on prostate cancer. Inference for causality and public health implications are, however, far from conclusive given the heterogeneity of results and the lack of dose and duration-risk relationships. Data on prostate cancer survival are still limited and inconsistent.

AB - Aspirin has been associated to a reduced risk of colorectal, and possibly of other cancers. Data from at least 25 observational studies also suggest a modest reduced risk of prostate cancer in regular aspirin users, with a summary relative risk, RR, of 0.91 (95 % confidence interval, CI, 0.86-0.96) overall, 0.87 (95 % CI 0.74-1.02) from nine case-control studies, and 0.92 (95 % CI 0.87-0.97) from 16 cohort studies. However, risk estimates are heterogeneous and there is no relation with frequency, dose, or duration of aspirin use. Data from randomized controlled trials of aspirin for the prevention of vascular events showed a nonsignificant reduced risk of death from prostate cancer after a latent period of five or more years (RR 0.52, 95 % CI 0.20-1.24) based on 37 deaths from prostate cancer from seven trials. The RR was 0.81 (95 % CI 0.61-1.06) after 20 years of follow-up, based on 210 cases from three trials with long-term follow-up. Thus, data from observational studies and clinical trials are compatible with a modest favorable effect of aspirin on prostate cancer. Inference for causality and public health implications are, however, far from conclusive given the heterogeneity of results and the lack of dose and duration-risk relationships. Data on prostate cancer survival are still limited and inconsistent.

UR - http://www.scopus.com/inward/record.url?scp=84896917309&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896917309&partnerID=8YFLogxK

U2 - 10.1007/978-3-642-45195-9-11

DO - 10.1007/978-3-642-45195-9-11

M3 - Article

C2 - 24531782

VL - 202

SP - 93

EP - 100

JO - Recent Results in Cancer Research

JF - Recent Results in Cancer Research

SN - 0080-0015

ER -